Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study To Evaluate The Safety and Tolerability Of Intravenous Infusion Of SNS01-T In Patients With Relapsed Or Refractory Multiple Myeloma, Mantle Cell Lymphoma, Or Diffuse Large B Cell Lymphoma

被引：3
|
作者：
Lust, John A.
Barranco, Charles
Usmani, Saad Z.
van Rhee, Frits
Hamadani, Mehdi
Thompson, John
Taylor, Catherine A.
Dondero, Richard
Browne, Leslie J.
Siegel, David
Bensinger, William I.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1950.1950
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1950
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study
    Kinoshita, Tomohiro
    Hatake, Kiyohiko
    Yamamoto, Kazuhito
    Higuchi, Yusuke
    Murakami, Satsuki
    Terui, Yasuhito
    Yokoyama, Masahiro
    Maruyama, Dai
    Makita, Shinichi
    Hida, Yukari
    Saito, Tomohisa
    Tobinai, Kensei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (01) : 70 - 77
  • [42] Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study
    Cheah, Chan Yoon
    Belada, David
    Fanale, Michelle A.
    Janikova, Andrea
    Czucman, Myron S.
    Flinn, Ian W.
    Kapp, Amy V.
    Ashkenazi, Avi
    Kelley, Sean
    Bray, Gordon L.
    Holden, Scott
    Seymour, John F.
    LANCET HAEMATOLOGY, 2015, 2 (04): : E166 - E174
  • [43] Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*
    Wilson, Wyndham H.
    Phillips, Tycel
    Popplewell, Leslie
    de Vos, Sven
    Chhabra, Saurabh
    Kimball, Amy S.
    Beaupre, Darrin
    Huang, Da Wei
    Wright, George
    Kwei, Kevin
    Ping, Jerry
    Neuenburg, Jutta K.
    Staudt, Louis M.
    LEUKEMIA & LYMPHOMA, 2021, 62 (09) : 2094 - 2106
  • [44] Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study
    Richardson, Paul G.
    Jagannath, Sundar
    Moreau, Philippe
    Jakubowiak, Andrzej J.
    Raab, Marc S.
    Facon, Thierry
    Vij, Ravi
    White, Darrell
    Reece, Donna E.
    Benboubker, Lotfi
    Zonder, Jeffrey
    Tsao, L. Claire
    Anderson, Kenneth C.
    Bleickardt, Eric
    Singhal, Anil K.
    Lonial, Sagar
    LANCET HAEMATOLOGY, 2015, 2 (12): : E516 - E527
  • [45] Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
    Ma, Xinran
    Li, Ling
    Zhang, Lei
    Fu, Xiaorui
    Li, Xin
    Wang, Xinhua
    Wu, Jingjing
    Sun, Zhenchang
    Zhang, Xudong
    Feng, Xiaoyan
    Chang, Yu
    Zhou, Zhiyuan
    Nan, Feifei
    Zhang, Jieming
    Li, Zhaoming
    Zhang, Mingzhi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 275 - 284
  • [46] Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Hari, Parameswaran
    Paba-Prada, Claudia E.
    Voorhees, Peter M.
    Frye, John
    Chang, Yu-Lin
    Moreau, Philippe
    Zonder, Jeffrey
    Boccia, Ralph
    Shain, Kenneth H.
    LEUKEMIA RESEARCH, 2019, 83
  • [47] Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective Study
    Ma, Xinran
    Li, Ling
    Zhang, Lei
    Li, Xin
    Fu, Xiaorui
    Wang, Xinhua
    Wu, Jingjing
    Zhang, Xudong
    Feng, Xiaoyan
    Zhou, Zhiyuan
    Chang, Yu
    Li, Zhaoming
    Young, Ken H.
    Zhang, Mingzhi
    BLOOD, 2019, 134
  • [48] Single arm phase II open label study of thalidomide in patients with refractory or relapsed diffuse large B cell lymphoma
    Hatton, C. S. R.
    Peniket, A.
    Tusold, A.
    Collins, G. P.
    Joyner, M.
    Lee, R.
    Mouncey, P.
    Smith, P.
    Lee, S-M
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 13 - 13
  • [49] A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Richardson, Paul G.
    Polepally, Akshanth R.
    Motwani, Monica
    Mu, Yunming
    Salman, Zeena
    Penugonda, Sudhir
    Moreau, Philippe
    BLOOD, 2020, 136
  • [50] Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Stiff, Patrick J.
    Maharaj, Michele
    Oliver, Katherine
    Callander, Natalie Scott
    BLOOD, 2016, 128 (22)
12345